Fitaro 1 mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for the management of type 2 diabetes mellitus. By mimicking the action of the naturally occurring incretin hormone GLP-1, Semaglutide helps regulate blood glucose levels, promotes satiety, and supports weight management in adults with type 2 diabetes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• GLP-1 Receptor Agonist

• Antidiabetic Agent

Indications

Fitaro 1 mg is indicated for:

• Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control in adults.

• Weight Management (Adjunct Therapy): May support weight reduction in overweight or obese patients with type 2 diabetes when combined with lifestyle interventions.

Pharmacology / Mode of Action

Semaglutide acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate glucagon secretion from alpha cells. This dual action helps lower fasting and postprandial glucose levels.

Additional pharmacological effects include:

• Delayed gastric emptying, reducing postprandial glucose spikes

• Central appetite regulation, increasing satiety and decreasing caloric intake

• Cardiovascular benefits: Semaglutide has demonstrated reduction in major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk.

Semaglutide is administered subcutaneously and has a prolonged half-life, allowing once-weekly dosing.

Dosage and Administration

• Initial Dose: 0.25 mg once weekly for the first 4 weeks (for titration).

• Maintenance Dose: Increase to 0.5 mg once weekly; may further escalate to 1 mg once weekly based on glycemic response and tolerability.

• Administer subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites with each dose.

• Not recommended for type 1 diabetes or diabetic ketoacidosis.

Side Effects

Common adverse reactions:

• Nausea, vomiting, diarrhea, constipation

• Abdominal pain, dyspepsia

• Decreased appetite, headache

Serious adverse reactions (rare):

• Pancreatitis (acute or chronic)

• Hypoglycemia (especially when used with sulfonylureas or insulin)

• Gallbladder disorders (including cholelithiasis and cholecystitis)

• Renal impairment in patients with pre-existing kidney disease

• Rare hypersensitivity reactions, including anaphylaxis

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)

• Hypersensitivity to Semaglutide or any excipients in the formulation

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Monitor patients for symptoms of pancreatitis, especially with persistent abdominal pain.

• Use caution in patients with gastrointestinal disease; delayed gastric emptying may worsen symptoms.

• May cause mild to moderate gastrointestinal discomfort during dose escalation; gradual titration can improve tolerability.

• Assess renal function periodically in patients with pre-existing kidney disease.

Use in Special Populations

• Pregnancy: Category C. Use only if benefits outweigh risks; avoid in breastfeeding due to unknown excretion in human milk.

• Elderly: No dose adjustment necessary, but monitor for dehydration from gastrointestinal side effects.

• Renal/Hepatic Impairment: No initial dose adjustment required; monitor closely for tolerability.

Storage Conditions

• Store refrigerated at 2–8°C.

• Protect from light.

• Do not freeze.

• Keep out of the reach of children.